Genetic and real-world clinical data, combined with empirical validation, nominate JAK-STAT signalling as a target for Alzheimer’s Disease therapeutic development
Alejo J. Nevado‐Holgado, Elena M. Ribé, Laura Thei, Laura Ines Furlong, Miguel Angel-Mayer, Jie Quan, Jill C. Richardson, Jonathan Cavanagh, Simon Lovestone
The paper combines GWAS, clinical data, and experimental models to identify JAK-STAT pathway dysregulation as a potential therapeutic target for Alzheimer’s disease.
bioRxiv · Aug 21, 2017 · PreprintBioinformatics